{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:53:49Z","timestamp":1766400829192,"version":"3.48.0"},"reference-count":44,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014565","name":"Bausch Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2587415","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:15:27Z","timestamp":1764170127000},"page":"2057-2070","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Quantifying treatment value under IRA: a case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures"],"prefix":"10.1080","volume":"28","author":[{"given":"Shanshan","family":"Wang","sequence":"first","affiliation":[{"name":"FTI Consulting","place":["Washington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Passos Chaves","sequence":"additional","affiliation":[{"name":"Bausch Health","place":["Bridgewater, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olamide","family":"Olujohungbe","sequence":"additional","affiliation":[{"name":"Bausch Health","place":["Bridgewater, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjana","family":"Muthukrishnan","sequence":"additional","affiliation":[{"name":"FTI Consulting","place":["Washington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditi","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"FTI Consulting","place":["Washington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8444-5979","authenticated-orcid":false,"given":"Jason","family":"Shafrin","sequence":"additional","affiliation":[{"name":"FTI Consulting","place":["Washington, USA"]},{"name":"University of Southern California","place":["Los Angeles, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.04130.x"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318157e500"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(99)80144-5"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.05.016"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0641-6"},{"key":"e_1_3_4_7_1","unstructured":"US Food and Drug Administration. Rifaximin prescribing information. 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021361s009lbl.pdf"},{"key":"e_1_3_4_8_1","unstructured":"Salix Pharmaceuticals. Xifaxan (rifaximin) tablets for oral use: prescribing information. 2025. https:\/\/shared.salix.com\/globalassets\/pi\/xifaxan550-pi.pdf."},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907893"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.6.750"},{"key":"e_1_3_4_11_1","unstructured":"Centers for Medicare & Medicaid Services. Medicare drug price negotiation program. 2025. https:\/\/www.cms.gov\/priorities\/medicare-prescription-drug-affordability\/overview\/medicare-drug-price-negotiation-program."},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2018.07.004"},{"key":"e_1_3_4_13_1","unstructured":"Centers for Medicare & Medicaid Services. Medicare drug price negotiation program: draft guidance implementation of sections 1191\u20131198 of the Social Security Act for initial price applicability year 2027 and manufacturer effectuation of the maximum fair price (MFP) in 2026 and 2027. 2024. https:\/\/www.cms.gov\/files\/document\/medicare-drug-price-negotiation-draft-guidance-ipay-2027-and-manufacturer-effectuation-mfp-2026-2027.pdf"},{"key":"e_1_3_4_14_1","unstructured":"Institute for Clinical and Economic Review. ICER\u2019s reference case for economic evaluations: elements and rationale. 2024. https:\/\/icer.org\/wp-content\/uploads\/2024\/02\/ICER_Reference-Case_For-Publication_102325.pdf."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-016-4031-7"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000181"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-023-01246-x"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.12.021"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-12-89"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.219"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14559"},{"key":"e_1_3_4_22_1","unstructured":"Institute for Clinical and Economic Review. Value assessment framework. ICER. 2023. https:\/\/icer.org\/wp-content\/uploads\/2023\/10\/ICER_2023_2026_VAF_For-Publication_070825.pdf"},{"key":"e_1_3_4_23_1","unstructured":"Drugs.com. lactulose prices coupons copay cards & patient assistance. 2025. https:\/\/www.drugs.com\/price-guide\/lactulose"},{"key":"e_1_3_4_24_1","unstructured":"Centers for Medicare & Medicaid Services. Medicare inpatient hospitals\u2014by provider and service. 2025. https:\/\/data.cms.gov\/provider-summary-by-type-of-service\/medicare-inpatient-hospitals\/medicare-inpatient-hospitals-by-provider-and-service\/data"},{"key":"e_1_3_4_25_1","unstructured":"US Bureau of Labor Statistics. Consumer price index for all urban consumers (CPI-U). 2025. https:\/\/data.bls.gov\/dataViewer\/view\/timeseries\/CUUR0000SAM"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2021.00343"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1050(199902)8:1<25::AID-HEC398>3.0.CO;2-H"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.10.014"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.36469\/001c.83387"},{"key":"e_1_3_4_30_1","unstructured":"National Council on Disability. Quality-adjusted life years and the devaluation of life with disability. 2019."},{"key":"e_1_3_4_31_1","unstructured":"Disability Rights Oregon. Oregon passes Senate Bill 1508-A to ban quality-adjusted life-years in Oregon!. 2024. https:\/\/www.droregon.org\/legislation\/sb1508-2024-oregon"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.11.009"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-023-01302-6"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-023-01659-7"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.05.005"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.10.003"},{"key":"e_1_3_4_37_1","unstructured":"Agency for Healthcare Research and Quality. Medical expenditure panel survey. 2025. https:\/\/meps.ahrq.gov\/mepsweb\/"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2024.102857"},{"key":"e_1_3_4_39_1","article-title":"New ICD-10 code aims to provide more insight into hepatic encephalopathy","author":"Klein H.","year":"2022","unstructured":"Klein H. New ICD-10 code aims to provide more insight into hepatic encephalopathy. Am J Manag Care. 2022; https:\/\/www.ajmc.com\/view\/new-icd-10-code-aims-to-provide-more-insight-into-hepatic-encephalopathy","journal-title":"Am J Manag Care"},{"key":"e_1_3_4_40_1","unstructured":"US Bureau of Labor Statistics. Table B-3. Average hourly and weekly earnings of all employees on private nonfarm payrolls by industry sector seasonally adjusted. 2025. https:\/\/www.bls.gov\/news.release\/empsit.t19.htm."},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X16644249"},{"key":"e_1_3_4_42_1","unstructured":"National Institute for Health and Care Excellence (NICE). Rifaximin for preventing episodes of overt hepatic encephalopathy: technology appraisal guidance. 2015. https:\/\/www.nice.org.uk\/guidance\/ta337\/chapter\/3-The-companys-submission."},{"issue":"1","key":"e_1_3_4_43_1","first-page":"26","article-title":"Demystifying ICER\u2019s equal value of life years gained metric","volume":"7","author":"O\u2019Day K","year":"2021","unstructured":"O\u2019Day K, Mezzio DJ. Demystifying ICER\u2019s equal value of life years gained metric. Value Outcomes Spotlight. 2021;7(1):26\u201328. https:\/\/www.ispor.org\/publications\/journals\/value-outcomes-spotlight\/vos-archives\/issue\/view\/overcoming-vaccine-hesitancy-injecting-trust-in-the-community\/demystifying-icer-s-equal-value-of-life-years-gained-metric.","journal-title":"Value Outcomes Spotlight"},{"key":"e_1_3_4_44_1","unstructured":"Agboola F Whittington MD Pearson SD. Advancing health technology assessment methods that support health equity. Institute for Clinical and Economic Review. 2023. https:\/\/icer.org\/wp-content\/uploads\/2022\/07\/ICER_Advancing-Health-Technology-Assessment-Methods-that-Support-Health-Equity_040523.pdf"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1515\/fhep-2024-0038"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2587415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:44:31Z","timestamp":1766400271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2587415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2587415"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2587415","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"type":"print","value":"1369-6998"},{"type":"electronic","value":"1941-837X"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}